Beginning in January 2016, Verona integron-mediated metallo-β-lactamase (VIM) producing carbapenem-resistant Enterobacteriaceae (CRE) were identified in Indiana. CRE are an emerging antibiotic-resistant public health threat. CRE spread might be largely due to the emergence of carbapenemase-producing CRE (CP-CRE). Carbapenemases are generally encoded on mobile genetic elements that are easily transferred between bacterial strains, greatly increasing their potential for spread (1–3). Furthermore, CP-CRE pose a risk because of their extensive drug resistance, increased associated mortality, and national lack of public health laboratory capacity for detection prior to 2016 (2,4,5).
The geographic distribution of carbapenemases varies globally. In the United States, the carbapenemase most frequently identified among Enterobacteriaceae is Klebsiella pneumoniae carbapenemase; others are less common and are most often identified in patients who recently received health care outside the United States. For example, VIM is frequently identified in southern Europe and Southeast Asia; however, it is infrequently reported from the United States (1–3).
In December 2015, the Indiana State Department of Health (ISDH) mandated reporting of CP-CRE, allowing for statewide identification and response to CP-CRE. To facilitate this reporting, the ISDH laboratories hosted CP-CRE workshops in which clinical laboratorians were trained in the detection of carbapenemases via currently available phenotypic testing methods. The ISDH laboratories provide CP-CRE characterization in real time, allowing for timely public health intervention. Upon detection of CP-CRE, the ISDH provides education and technical assistance to health care facilities to ensure rapid implementation of proper infection control procedures. Each patient from whom a CP-CRE isolate is identified is investigated by the local health department to characterize demographics and CP-CRE risk factors, including recent health care exposures and international travel during the preceding 6 months.
During January 2016–December 2017, 649 CP-CRE isolates were reported across Indiana, including nine VIM-producing CP-CRE (VIM-CRE) isolates from seven patients. VIM was the most commonly identified carbapenemase after Klebsiella pneumoniae carbapenemase. Seven different species were identified from the nine VIM-producing isolates; one patient was found be colonized or infected with three different VIM-producing organisms over a 15-month period (Table). All seven patients had overnight stays in Indiana health care facilities, and none had documented international travel in the 6 months preceding specimen collection.
TABLE. Verona integron-mediated metallo-β-lactamase–producing carbapenem-resistant Enterobacteriaceae (N = 9) isolated from seven patients in health care facilities — Indiana, January 1, 2016–December 31, 2017.
Patient | Age (yrs) | Sex | Specimen collection date | Specimen | Organism | Health care exposure history in 6 months preceding specimen collection | Antibiotic use in 6 months preceding specimen collection | Other resistant organisms identified in 6 months preceding specimen collection |
---|---|---|---|---|---|---|---|---|
1* |
36 |
M |
01/19/2016 |
Wound |
Proteus mirabilis
|
ACH |
Unknown |
CRE, MDR-AB, ESBL |
01/27/2017 |
Urine |
Klebsiella pneumoniae
|
ACH |
Yes |
CP-CRE, MDR-AB, MRSA |
|||
03/24/2017 |
Urine |
Providencia rettgeri
|
ACH |
Yes |
CP-CRE, MDR-AB, MRSA |
|||
2 |
28 |
M |
03/21/2016 |
Wound |
Enterobacter cloacae complex |
ACH |
Yes |
MRSA |
3 |
67 |
M |
10/01/2016 |
BAL |
Enterobacter cloacae complex |
ACH, LTACH, LTCF |
Yes |
CRE, MRSA, MDR-PA, CDI |
4 |
94 |
F |
12/12/2016 |
Urine |
Klebsiella pneumoniae
|
LTCF |
Yes |
VRE |
5 |
36 |
F |
08/08/2017 |
Sputum |
Citrobacter freundii complex |
ACH |
Yes |
None |
6 |
75 |
M |
09/01/2017 |
Urine |
Klebsiella pneumoniae
|
ACH, LTACH |
Unknown |
None |
7 | 56 | F | 11/28/2017 | Urine | Klebsiella oxytoca | ACH | Yes | None |
Abbreviations: ACH = acute care hospital; BAL = bronchoalveolar lavage; CDI = Clostridioides difficile infection; ESBL = extended-spectrum β-lactamase; F = female; LTACH = long term acute care hospital; LTCF = long term care facility; M = male; MDR-AB = multidrug-resistant Acinetobacter baumannii complex; MDR-PA = multidrug-resistant Pseudomonas aeruginosa; MRSA = methicillin-resistant Staphylococcus aureus; VRE = vancomycin-resistant Enterococcus.
* Single patient with multiple isolates.
Improved isolate submission and expanded capacity to detect carbapenemase-producing organisms have identified VIM-CRE as an emerging resistance problem in Indiana. All patients with VIM-CRE reported recent health care in Indiana but had not traveled outside the country, suggesting VIM transmission within Indiana health care facilities. Notably, although VIM remains one of the least frequently reported carbapenemases among CRE in the United States, Indiana and neighboring states account for 29 (71%) of the 41 VIM-CRE reported to CDC to date, suggesting possible regional emergence of this resistance mechanism (6). This finding highlights the important role of state public health laboratories in facilitating identification and reporting of CRE by clinical laboratories and in testing isolates to identify important CRE resistance mechanisms, including all five carbapenemases of major public health concern.* Although such testing has had limited availability in clinical and public health laboratories, recent CDC investments to create the Antibiotic Resistance Laboratory Network have increased carbapenemase testing and CRE screening nationwide. This testing will provide better understanding of CP-CRE epidemiology throughout the United States, including important regional differences in emerging carbapenemases (6). Once CP-CRE are identified, health department epidemiologists can work to ensure prompt implementation of infection control interventions. This collaboration between epidemiologists and laboratorians to identify, describe, and respond to emerging drug resistance is needed for containment efforts.
Conflict of Interest: No conflicts of interest were reported.
Footnotes
Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM), Verona integron-mediated metallo-β-lactamase (VIM), imipenemase (IMP), and oxacillinase-48-like carbapenemase (OXA-48).
References
- 1.Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151–61. 10.1128/AAC.45.4.1151-1161.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791–8. 10.3201/eid1710.110655 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2017;8:460–9. 10.1080/21505594.2016.1222343 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Tamma PD, Goodman KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 2017;64:257–64. 10.1093/cid/ciw741 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hrabák J, Chudáčková E, Papagiannitsis CC. Detection of carbapenemases in Enterobacteriaceae: a challenge for diagnostic microbiological laboratories. Clin Microbiol Infect 2014;20:839–53. 10.1111/1469-0691.12678 [DOI] [PubMed] [Google Scholar]
- 6.CDC. Healthcare-associated infections: tracking CRE. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/hai/organisms/cre/trackingcre.html